Demographic and clinical characteristics of malignant multiple sclerosis

Neurology

Volumn 76, Issue 23, 2011, Pages 1996-2001

  Gholipour, T ^a   Healy, B ^a   Baruch, N F ^a   Weiner, H L ^a   Chitnis, T ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID;

ADULT; ARTICLE; BRAIN STEM; CLINICAL FEATURE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DATA BASE; DEMOGRAPHY; DISEASE COURSE; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; GROUPS BY AGE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; MULTIPLE SCLEROSIS; ONSET AGE; PREDICTOR VARIABLE; PRIORITY JOURNAL; RELAPSE; SEX DIFFERENCE; SMOKING; SURVIVAL RATE; SUSTAINED MALIGNANT MULTIPLE SCLEROSIS; TRANSIENT MALIGNANT MULTIPLE SCLEROSIS;

ADULT; AGE OF ONSET; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MOVEMENT DISORDERS; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; RECURRENCE; SEX DISTRIBUTION; SMOKING;

EID: 79958736431     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31821e559d     Document Type: Article

References (29)

1. Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain 2006;129:606-616. (Pubitemid 43278223)
2. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000;343:1430-1438.
3. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study: I: clinical course and disability. Brain 1989;112:133-146. (Pubitemid 19056478)
4. Tremlett H, Paty D, Devonshire V. Disability progression in multiple sclerosis is slower than previously reported. Neurology 2006;66:172-177. (Pubitemid 43970148)
5. Leray E, Yaouanq J, Le Page E, et al. Evidence for a twostage disability progression in multiple sclerosis. Brain 2010;133:1900-1913.
6. Weiner HL. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease? Ann Neurol 2009;65:239-248.
7. DeLuca GC, Ramagopalan SV, Herrera BM, et al. An extremes of outcome strategy provides evidence that multiple sclerosis severity is determined by alleles at the HLADRB1 locus. Proc Natl Acad Sci USA 2007;104:20896-20901.
8. Pittock SJ, McClelland RL, Mayr WT, et al. Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study. Ann Neurol 2004;56: 303-306. (Pubitemid 39037929)
9. Weinshenker BG, Rice GP, Noseworthy JH, Carriere W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: a geographically based study: 3: multivariate analysis of predictive factors and models of outcome. Brain 1991;114:1045-1056.
10. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 2003;126:770-782. (Pubitemid 36372978)
11. Gauthier SA, Glanz BI, Mandel M, Weiner HL. A model for the comprehensive investigation of a chronic autoimmune disease: the multiple sclerosis CLIMB study. Autoimmun Rev 2006;5:532-536. (Pubitemid 44488756)
12. Greenland S, Rothman KJ. Measures of occurrence. In: Rothman KJ, Greenland S, Lash TL, eds. Modern Epidemiology, 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2008.
13. Fray MP. Weighted logrank tests and NPMLE for interval censored data. In: R package version 0.9-9.6. Available at: http://CRAN.R-project.org/package- interval. Accessed August 1, 2010.
14. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey: National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907-911.
15. Roxburgh RH, Seaman SR, Masterman T, et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 2005;64:1144-1151.
16. Cree BA, Khan O, Bourdette D, et al. Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. Neurology 2004;63:2039-2045. (Pubitemid 39636249)
17. Debouverie M, Lebrun C, Jeannin S, Pittion-Vouyovitch S, Roederer T, Vespignani H. More severe disability of North Africans vs Europeans with multiple sclerosis in France. Neurology 2007;68:29-32. (Pubitemid 46058547)
18. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis: part II: noninfectious factors. Ann Neurol 2007;61:504-513. (Pubitemid 47068132)
19. Healy BC, Ali EN, Guttmann CR, et al. Smoking and disease progression in multiple sclerosis. Arch Neurol 2009;66:858-864.
20. Hernan MA, Jick SS, Logroscino G, Olek MJ, Ascherio A, Jick H. Cigarette smoking and the progression of multiple sclerosis. Brain 2005;128:1461-1465. (Pubitemid 40826198)
21. Sopori ML, Kozak W. Immunomodulatory effects of cigarette smoke. J Neuroimmunol 1998;83:148-156. (Pubitemid 28280961)
22. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis: part I: the role of infection. Ann Neurol 2007;61:288-299. (Pubitemid 46676728)
23. Ebers GC, Koopman WJ, Hader W, et al. The natural history of multiple sclerosis: a geographically based study: 8: familial multiple sclerosis. Brain 2000;123:641-649. (Pubitemid 30099546)
24. Confavreux C. Defining the natural history of MS: the need for complete data and rigorous definitions. Mult Scler 2008;14:289-291. (Pubitemid 351676422)
25. Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 2003;61:1528-1532. (Pubitemid 37505574)
26. Tremlett H, Yousefi M, Devonshire V, Rieckmann P, Zhao Y. Impact of multiple sclerosis relapses on progression diminishes with time. Neurology 2009;73:1616-1623.
27. Weiner HL, Cohen JA. Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects. Mult Scler 2002;8:142-154. (Pubitemid 34256752)
28. Hartung HP, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002; 360:2018-2025. (Pubitemid 36026580)
29. Fox EJ. Management of worsening multiple sclerosis with mitoxantrone: a review. Clin Ther 2006;28:461-474. (Pubitemid 44208782)